A company set up by a hedge fund, with no background or expertise in pharmacology, arranged to get rights to a drug that was developed by researchers at Emory University on a $16 million contract with the government.
The drug, EIDD-2801, is thought to be a potential treatment for the coronavirus.
Shortly after arranging to buy the rights to the drug, the company turned around and sold them to Merck, presumably for a substantial profit.
Neither the United States of America nor the United Kingdom have agreed to share the fruits of research with the world, leaving open the possibility that one or more of their drug companies will take advantage of research that was widely shared to develop a vaccine or treatment on which they will claim a patent monopoly, and then charge very high prices.
https://www.commondreams.org/views/2020/06/20/patents-and-pandemic-again
The drug, EIDD-2801, is thought to be a potential treatment for the coronavirus.
Shortly after arranging to buy the rights to the drug, the company turned around and sold them to Merck, presumably for a substantial profit.
Neither the United States of America nor the United Kingdom have agreed to share the fruits of research with the world, leaving open the possibility that one or more of their drug companies will take advantage of research that was widely shared to develop a vaccine or treatment on which they will claim a patent monopoly, and then charge very high prices.
https://www.commondreams.org/views/2020/06/20/patents-and-pandemic-again
No comments:
Post a Comment